Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...
Yahoo Finance52 分钟
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with ...
WILMINGTON, Del., November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) ...